Keytruda

Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more
Merck, Bristol-Myers cancer drugs both beat expectations, but Merck beats them a little more
CNBC
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Yervoy
non-small cell lung cancer
AACR
Flag link:
Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma
Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma
CP Wire
Merck
Keytruda
melanoma
anti-PD-1 immunotherapy
Flag link:
Keytruda Adjuvant Therapy Study Shows Reduced the Risk of Disease Recurrence or Death by More Than 40 Percent Compared to Placebo in Stage III Melanoma
Merck
Keytruda
melanoma
Flag link:
With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge
With big Keytruda and Opdivo data coming at AACR, analyst hands Merck the early edge
Fierce Pharma
Merck
Bristol-Myers Squibb
Keytruda
Opdivo
Yervoy
AACR
Flag link:
Merck's stock surges after positive Keytruda trial results
Merck's stock surges after positive Keytruda trial results
Marketwatch
Merck
Keytruda
clinical trials
metastatic non-small cell lung cancer
Flag link:
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Flag link:
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Incyte's stock plunges, Merck shares fall after disappointing study results of melanoma treatment
Marketwatch
Incyte
Merck
melanoma
epacadostat
Keytruda
clinical trials
metastatic melanoma
Flag link:
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer (TSRO)
CP Wire
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials vaccines
Flag link:
Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer
Tesaro
Zejula
Merck
Keytruda
platinum-resistant ovarian cancer
niraparib
clinical trials
Flag link:
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Roche's Tecentriq triumphs in squamous lung cancer. Can it make its mark against Merck?
Fierce Pharma
Roche
Tecentriq
squamous non-small cell lung cancer
Merck
Keytruda
Flag link:
Merck's Keytruda shows up its rivals with NICE backing in bladder cancer
Merck's Keytruda shows up its rivals with NICE backing in bladder cancer
Fierce Pharma
Merck
Keytruda
NICE
bladder cancer
Flag link:
Incyte study could bring lessons for cancer immunotherapy
Incyte study could bring lessons for cancer immunotherapy
Biopharma Dive
Incyte
cancer immunotherapy
metastatic melanoma
Merck
Keytruda
Flag link:
[video]How Convenience Can Give Drugmakers a Competitive Edge
[video]How Convenience Can Give Drugmakers a Competitive Edge
Motley Fool
convenience
Merck
Bristol-Myers Squibb
dosing
Opdivo
Keytruda
Flag link:
Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star
Doubling down on the Keytruda franchise, Merck pays $300M and promises $5B-plus to partner with Eisai on its budding cancer star
Endpoints
Merck
Keytruda
Eisai
Lenvima
Flag link:
Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs
Merck says Keytruda's explosive growth prompts need for new Ireland plant with 350 jobs
Fierce Pharma
Merck
Keytruda
Ireland
hirings
drug manufacturing
Flag link:
Merck quarterly profit beats on Keytruda demand
Merck quarterly profit beats on Keytruda demand
Yahoo/Reuters
Merck
earnings
Keytruda
Flag link:
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
5 Highest-Growth Drugs of 2018 -- and Who Will Get Rich from Them
Motley Fool
Merck
Keytruda
AbbVie
Humira
Mavyret
Bristol-Myers Squibb
Eliquis
Pfizer
Ibrance
Flag link:
Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda
Merck & Co.’s shares rise over 7% thanks to new positive clinical results from Keytruda
GoinPharma
Merck
Keytruda
non-squamous cell non-small cell lung cancer
Flag link:
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
Merck & Co. and Eisai seek to undermine BMS’ position in kidney cancer treatment sector
GoinPharma
Eisai
Merck
Bristol-Myers Squibb
kidney cancer
Keytruda
Lenvima
Opdivo
Flag link:
Merck's Keytruda extends lung cancer survival in combination trial
Merck's Keytruda extends lung cancer survival in combination trial
Yahoo/Reuters
Merck
Keytruda
lung cancer
clinical trials
Flag link:

Pages